Table of Content

1. Introduction to Bangladesh Pharmaceutical Market
  1.1 Overview
  1.2 Current Market Scenario

2. Bangladesh - Cancer Prevalence & Statistics
  2.1 Overview
  2.2 By Gender
  2.3 By Age
  2.4 By Leading Cancer Type
    2.4.1 Oesophagus Cancer
    2.4.2 Lip,Oral Cavity Cancer
    2.4.3 Breast Cancer
    2.4.4 Lung Cancer
   2.4.5 Cervix Uteri Cancer

3. Bangladesh - Diabetes Prevalence & Statistics
  3.1 By Population
  3.2 By Diabetes Type
  3.2.1 Type 1 Diabetes
  3.2.2 Type 2 Diabetes
  3.3 By Age & Gender
  3.4 Obesity & Overweight

4. Bangladesh HIV Infection - Prevalence & Statistics

5. Bacterial & Viral Infections in Bangladesh - Prevalence& Statistics
  5.1 Hepatitis-B
  5.2 Diarrheal Disease
  5.3 Tuberculosis
  5.4 Pneumonia & Influenza

6. Cardiovascular Diseases in Bangladesh - Prevalence & Statistics
  6.1 Hypertension
  6.2 Coronary Heart Disease & Stroke

7. Bangladesh Pharmaceutical Market Segmentation
  7.1 By Product - Generics & Patented Drugs
  7.2 By Treatment System
  7.3 By Local & Multinational Companies
  7.4 By Therapeutic Class
  7.5 By Trade - Import & Export Market

8. Bangladesh Pharmaceutical Market Leading Drugs Insight - Availability, Dosage & Price Analysis
  8.1 Seclo (Omeprazole)
  8.2 Sergel (Esomeprazole)
  8.3 Maxpro (Esomeprazole)
  8.4 Pantonix (Pantoprazole)
  8.5 CEF-3 (Cefixime Trihydrate)
  8.6 Mixtard 30 (Insulin Human & Isophane Insulin Human)
  8.7 Napa Extra (Paracetamol & Caffeine)
  8.8 Losectil (Omeprazole)
  8.9 Napa (Paracetamol)
  8.10 Exium (Esomeprazole)

9. Bangladesh Pharmaceutical Market - Clinical Trials Insight
  9.1 By Phase
  9.2 By Recruiting Status
  9.3 By Indication

10. Bangladesh Pharmaceutical Market Dynamics
  10.1 Drivers for Bangladesh Pharmaceutical Market
  10.2 Challenges for Bangladesh Pharmaceutical Market
 

11. Bangladesh Pharmaceutical Market Future Outlook

12. Competitive Landscape
  12.1 Local Companies
    12.1.1 Square Pharmaceuticals
    12.1.2 Incepta Pharma
    12.1.3 Beximco Pharma
    12.1.4 Opsonin Pharma
    12.1.5 Ranata Limited
    12.1.6 Beacon Pharmaceuticals
    12.1.7 Chemist Laboratories 
    12.1.8 Central Pharmaceuticals
    12.1.9 Delta Pharma
    12.1.10 Everest Pharmaceuticals
    12.1.11 Desh pharmaceuticals
    12.1.12 Decent Pharmaceuticals
    12.1.13 FNF Pharmaceuticals

12.2 Multinational Companies
    12.2.1 Amgen
    12.2.2 Eli - Lilly
    12.2.3 Merck
    12.2.4 Pfizer
    12.2.5 GlaxoSmithKline 
    12.2.6 Roche
    12.2.7 AstraZeneca 
    12.2.8 Genentech
    12.2.9 Sanofi
    12.2.10 Novo Nordisk

Figure 1-1: Bangladesh – Per Capita Healthcare Expenditure (US$), 2015 - 2017
Figure 1-2: Bangladesh – Healthcare Expenditure (US$ Billion), 2015 - 2017
Figure 1-3: Bangladesh – Pharmaceutical Market Share by Local v/s Multinational Companies (BDT/US$ Billion), 2018
Figure 1-4: Bangladesh – Pharmaceutical Market Size (BDT/US$ Billion), 2015 - 2019
Figure 1-5: Bangladesh – Pharmaceutical Market Size (BDT/US$ Billion), 2020 - 2025
Figure 1-6: Bangladesh – Production Share of Generics & Patented Drugs (%), 2018
Figure 1-7: Bangladesh – Pharmaceutical Export Market (US$ Million), 2015 - 2019

Figure 2-1: Bangladesh – Newly Diagnosed Cancer Cases, 2018, 2020 & 2025
Figure 2-2: Bangladesh – Number of Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-3: Bangladesh – Newly Diagnosed Cancer Cases by Leading Cancer Type, 2018
Figure 2-4: Bangladesh – Newly Diagnosed Cancer Cases by Leading Cancer Type (%), 2018
Figure 2-5: Bangladesh – Cancer Related Deaths by Leading Cancer Type, 2018
Figure 2-6: Bangladesh – Cancer Related Deaths by Leading Cancer Type (%), 2018
Figure 2-7: Bangladesh – Newly Diagnosed Cancer Cases by Gender, 2018
Figure 2-8: Bangladesh – Cancer Related Deaths by Gender, 2018
Figure 2-9: Bangladesh – Newly Diagnosed Cancer Cases by Gender (%), 2018
Figure 2-10: Bangladesh – Newly Diagnosed Male Cancer Cases, 2018, 2020 & 2025
Figure 2-11: Bangladesh – Newly Diagnosed Female Cancer Cases, 2018, 2020 & 2025
Figure 2-12: Bangladesh – Male Cancer Cases by Cancer Type, 2018
Figure 2-13: Bangladesh – Female Cancer Cases by Cancer Type (%), 2018
Figure 2-14: Bangladesh – Age Standardized Incidence Rate of Leading Male Cancer (Per 100’000 People), 2018
Figure 2-15: Bangladesh – Age Standardized Incidence Rate of Leading Female Cancer (Per 100’000 People), 2018
Figure 2-16: Bangladesh – Newly Diagnosed Cancer Cases by Age, 2018
Figure 2-17: Bangladesh – Newly Diagnosed Cancer Cases by Age (%), 2018
Figure 2-18: Bangladesh – Cancer Related Deaths by Age, 2018
Figure 2-19: Bangladesh – Newly Diagnosed Cancer Cases by Age (%), 2018
Figure 2-20: Bangladesh – Oesophagus Cancer Cases, 2018, 2020 & 2025
Figure 2-21: Bangladesh – Oesophagus Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-22: Bangladesh – Age-Standardized Oesophagus Cancer Incidence & Mortality Rate (Per 100’000 People), 2018
Figure 2-23: Bangladesh – Lip,Oral Cavity Cancer Cases, 2018, 2020 & 2025
Figure 2-24: Bangladesh – Lip, Oral Cavity Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-25: Bangladesh – Age-Standardized  Lip, Oral Cavity Cancer Incidence & Mortality Rate (Per 100’000 People), 2018
Figure 2-26: Bangladesh – Breast Cancer Cases, 2018, 2020 & 2025
Figure 2-27: Bangladesh – Breast Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-28: Bangladesh – Age-Standardized Breast Cancer Incidence & Mortality Rate (Per 100’000 People), 2018
Figure 2-29: Bangladesh – Lung Cancer Cases, 2018, 2020 & 2025
Figure 2-30: Bangladesh – Lung Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-31: Bangladesh – Age-Standardized Lung Cancer Incidence & Mortality Rate (Per 100’000 People), 2018
Figure 2-32: Bangladesh – Cervix Uteri Cancer Cases, 2018, 2020 & 2025
Figure 2-33: Bangladesh – Cervix Uteri Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-34: Bangladesh – Age-Standardized Cervix Uteri Cancer Incidence & Mortality Rate (Per 100’000 People), 2018

Figure 3-1: Bangladesh - Adult Diabetic Population (Million), 2010 & 2019
Figure 3-2: Bangladesh - Estimated Number of Adult Diabetic Population (Million), 2030 & 2045
Figure 3-3: Bangladesh - Diagnosed v/s Undiagnosed Adult Diabetic Population (Million), 2019
Figure 3-4: Bangladesh - Diagnosed v/s Undiagnosed Adult Diabetic Population Share (%), 2019
Figure 3-5: Bangladesh - Age Adjusted Diabetes Prevalence Rate (%), 2019, 2030 & 2045
Figure 3-6: Bangladesh - Diabetes Related Deaths, 2010 & 2019
Figure 3-7: Bangladesh - Population Estimates (Million), 2019, 2020, 2025 & 2030
Figure 3-8: Bangladesh - Adult Diabetes Cases by Type (Million), 2019
Figure 3-9: Bangladesh - Diabetes Cases by Type (%), 2019
Figure 3-10:  Bangladesh - Type 1 Diabetic Adult Population (Million), 2019, 2025 & 2045
Figure 3-11: Bangladesh - Total & Newly Diagnosed Type 1 Diabetic Cases in Age below 19 Years, 2019
Figure 3-12: Bangladesh – Type 2 Diabetic Population (Million), 2019, 2030 & 2045
Figure 3-13: Bangladesh - Diabetes Prevalence Rate by Gender (%), 2016
Figure 3-14: Bangladesh - Newly Diagnosed Type 1 Diabetes Cases in Children by Age, 2019
Figure 3-15: Bangladesh - Type 1 Diabetes Cases in Children by Age, 2019
Figure 3-16: Bangladesh - Type 1 Diabetes Cases in Children by Age (%), 2019
Figure 3-17: Bangladesh - Obesity Prevalence Rate by Gender (%), 2019
Figure 3-18: Bangladesh - Obese Population v/s Total Population (Million), 2020

Figure 4-1: Bangladesh – Total HIV Cases & Newly Diagnosed HIV Cases, 2018
Figure 4-2: Bangladesh – HIV Cases, 2010, 2015 & 2018
Figure 4-3: Bangladesh – New Diagnosed HIV Cases, 2010, 2015 & 2018
Figure 4-4: Bangladesh – New Diagnosed HIV Cases by Gender, 2018
Figure 4-5: Bangladesh - New Diagnosed HIV Cases by Gender (%), 2018
Figure 4-6: Bangladesh – Total HIV Cases by Age & Gender, 2018
Figure 4-7: Bangladesh – Number of HIV Patients by Known Status & ART Therapy, 2018
Figure 4-8: Bangladesh – Number of HIV Patients by Known Status & ART Therapy (%), 2018
Figure 4-9: Bangladesh – Share of ART Receiving Patients In Total HIV Patients (%), 2015 - 2018
Figure 4-10: Bangladesh – Number of ART Receiving Patients by Gender, 2018
Figure 4-11: Bangladesh – Number of ART Receiving Patients by Gender (%), 2018
Figure 4-12: Bangladesh – ART Receiving Patients by Age, 2018
Figure 4-13: Bangladesh – Patients with Late HIV Diagnosis by CD4 Cell Count (%), 2018

Figure 5-1: Bangladesh – Known & Unknown Hepatitis-B Infection Cases (%), 2018
Figure 5-2: Bangladesh – Risk of Developing other Liver Complication due to Hepatitis-B (%), 2018
Figure 5-3: Bangladesh – Number of Children Born with Hepatitis-B Infection (%), 2018
Figure 5-4: Bangladesh – Number of Diarrhea Related Deaths (Per 1 Million People), 2003, 2013 & 2018
Figure 5-5: Bangladesh – Diarrhea Cases by Causative Microorganism, 2018
Figure 5-6: Bangladesh – Diarrhea Related Deaths v/s Others, 2018
Figure 5-7: Bangladesh – New/Relapsed Tuberculosis Cases & Deaths by Type, 2018
Figure 5-8: Bangladesh – Estimated Tuberculosis Incidence Rate by Type, 2018
Figure 5-9: Bangladesh – New & Relapsed TB Cases v/s Number of Estimated TB Cases, 2018
Figure 5-10: Bangladesh – New & Relapsed TB Cases by Gender & Age, 2018
Figure 5-11: Bangladesh – Adult TB Cases by Gender, 2018
Figure 5-12: Bangladesh – Pneumonia  Related Deaths in Age less than 5 Years, 2018
Figure 5-13: Bangladesh – Pneumonia Related Deaths in Age less than 5 Years (%), 2018

Figure 6-1: Bangladesh – Total Population v/s Population with Hypertension (Million), 2020
Figure 6-2: Bangladesh – Share of Hypertensive Patient (%), 2020
Figure 6-3: Bangladesh – Hypertensive Population by Status (Million), 2020
Figure 6-4: Bangladesh – Hypertensive Population by Status (Million), 2020
Figure 6-5: Bangladesh – Hypertensive Prevalence in Urban & Rural Area (%), 2017
Figure 6-6: Bangladesh – Hypertensive Prevalence by Gender (%), 2017
Figure 6-7: Bangladesh – Hypertensive Prevalence by Age (%), 2017
Figure 6-8: Bangladesh – Number of Coronary Heart Disease & Stroke Related Deaths, 2018
Figure 6-9: Bangladesh –Coronary Heart Disease & Stroke Related Deaths v/s Deaths Related to Other Complications, 2018
Figure 6-10: Bangladesh – Age adjusted Death Rate of Coronary Heart Disease & Stroke (Per 100’000), 2018

Figure 7-1: Bangladesh – Generic Pharmaceutical Market Size (BDT/US$ Billion), 2016 - 2019
Figure 7-2: Bangladesh – Generic Pharmaceutical Market Size (BDT/US$ Billion), 2020 - 2025
Figure 7-3: Bangladesh – Top 10 Generic Pharmaceutical Company by Market Share (%), 2017
Figure 7-4: Bangladesh – Top 10 Generic Pharmaceutical Company by Market Share (%), 2017
Figure 7-5: Bangladesh – Patented Pharmaceutical Market Size (BDT/US$ Billion), 2020 - 2025
Figure 7-6: Bangladesh – Number of Registered Allopathic  Manufacturers, Drugs, Generics & Retail Pharmacies, 2018
Figure 7-7: Bangladesh – Number of Registered Homeopathic Manufacturers, Drugs & Retail Pharmacies, 2018
Figure 7-8: Bangladesh – Number of Registered Unani Manufacturers, Drugs & Retail Pharmacies, 2018
Figure 7-9: Bangladesh – Number of Registered Ayurvedic Manufacturers, Drugs & Retail Pharmacies, 2018
Figure 7-10: Bangladesh – Local Pharmaceutical Market Size (BDT/US$ Billion), 2015 - 2018
Figure 7-11: Bangladesh – Pharmaceutical Market Size of Multinational Companies (BDT/US$ Billion), 2015 - 2018
Figure 7-12: Bangladesh – Pharmaceutical Market Size by Type of Companies (BDT/US$ Billion), 2025
Figure 7-13: Bangladesh – Share of Leading Local Pharma Company in Total Pharmaceutical Market (%), Q2 2017
Figure 7-14: Bangladesh – Share of Leading MNCs Pharma Company in Total Pharmaceutical Market (%), Q2 2017
Figure 7-15: Bangladesh – Pharmaceutical Market Size by Therapeutic Class (BDT/US$ Billion), 2018
Figure 7-16: Bangladesh – Year over Year Growth Rate by Therapeutic Segment (%), 2018
Figure 7-17: Bangladesh – Share of Gastroenterological Class in Total Pharma Market (%), 2015 - 2018
Figure 7-18: Bangladesh – Share of Anti-Infectives in Total Pharma Market (%), 2015 - 2018
Figure 7-19: Bangladesh – Share of Pain Killers in Total Pharma Market (%), 2015 - 2018
Figure 7-20: Bangladesh – Pharmaceutical Export Market (US$ Million), 2019 - 2025
Figure 7-21: Bangladesh – Pharmaceutical Export & Import Market (US$ Million), 2019
Figure 7-22: Bangladesh – Share of Imported API in Total API Consumption (%), 2019
Figure 7-23: Bangladesh – Pharmaceutical Export Earnings by Countries (US$ Million), 9 Month’2019
Figure 7-24: Bangladesh – Bxpharma Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
Figure 7-25: Bangladesh – Square Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
Figure 7-26: Bangladesh – Ranata Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
Figure 7-27: Bangladesh – ACME Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018

Figure 8-1: Seclo – Price for 120 Capsules, 5 Capsules & Price per Unit capsule of 20mg (BDT/US$), July’2020
Figure 8-2: Seclo – Price for 120 Capsules, 5 Capsules & Price per Unit capsule of 40mg (BDT/US$), July’2020
Figure 8-3: Seclo – Recommended Oral Dose by Indication (mg/day), July’2020
Figure 8-4: Seclo – Recommended IV Dose by Indication (mg/day), July’2020
Figure 8-5: Sergel – Price for 100 Capsules & Price per Unit Capsule of 20mg (BDT/US$), July’2020
Figure 8-6: Sergel – Price for 50 Capsules & Price per Unit Capsule of 40mg (BDT/US$), July’2020
Figure 8-7: Sergel – Price for 30 Tablets & Price per Unit Tablet of 20mg (BDT/US$), July’2020
Figure 8-8: Seclo – Price for 30 Tablets & Price per Unit Tablet of 40mg (BDT/US$), July’2020
Figure 8-9: Sergel – Recommended Adult & Pediatric Dose (mg/day)
Figure 8-10: Maxpro – Price for 140 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July’2020
Figure 8-11: Maxpro – Price for 5 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July’2020
Figure 8-12: Maxpro – Price for 40 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July’2020
Figure 8-13: Maxpro – Price for 10 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July’2020
Figure 8-14: Maxpro – Price for 100 Capsules, 14 Capsules & Price per Unit Capsule of 20mg (BDT/US$), July’2020
Figure 8-15: Maxpro – Price for 60 Capsules & Price per Unit Capsule of 40mg (BDT/US$), July’2020
Figure 8-16: Sergel – Recommended Adult & Pediatric Dose (mg/day)
Figure 8-17: Pantonix – Price for 70 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July’2020
Figure 8-18: Pantonix – Price for 14 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July’2020
Figure 8-19: Pantonix – Price for 70 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July’2020
Figure 8-20: Pantonix – Price for 14 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July’2020
Figure 8-21: Pantonix – Recommended Minimum & Maximum Oral Dose (mg/day)
Figure 8-22: Pantonix – Minimum & Maximum Duration of Oral Therapy (Weeks)
Figure 8-23: Pantonix – Recommended Minimum & Maximum Intravenous Dose (mg/day)
Figure 8-24: Cef-3 – Price for 14 Capsule & Price per Unit Capsule of 200mg (BDT/US$), July’2020
Figure 8-25: Cef-3 – Price for 6 Capsules, 12 Capsules & Price per Unit Capsule of 400mg (BDT/US$), July’2020
Figure 8-26: Cef-3 Suspension – Price for 30ml, 50ml & 75ml Suspension of Dose 100mg/5ml (BDT/US$), July’2020
Figure 8-27: Cef-3 Suspension – Price for 50ml Supply & Price per ml of 200mg/5ml Suspension (BDT/US$), July’2020
Figure 8-28: Cef-3 Pediatric Drops – Price for 21ml Supply & Price per ml of 25mg/ml Drops (BDT/US$), July’2020
Figure 8-29: Cef-3 – Recommended Minimum & Maximum Dose for Gonorrhea (mg/day)
Figure 8-30: Cef-3 – Usual Adult & Pediatric Dose (mg/day)
Figure 8-31: Mixtard 30 – Price for 10ml & Price per ml of 40IU/ml Vial (BDT/US$), July’2020
Figure 8-32: Mixtard 30 – Price for 10ml & Price per ml of 100 IU/ml Vial (BDT/US$), July’2020
Figure 8-33: Mixtard 30 – Price for 5 Penfill Supply & Price for Single Penfill of 100 IU/ml Vial (BDT/US$), July’2020
Figure 8-34: Mixtard 30 – Price for 5 Flexpen Supply & Price for Single Flexpen of 100 IU/ml Vial (BDT/US$), July’2020
Figure 8-35: Mixtard 30 – Recommended Minimum & Maximum Dose for Type 1 Diabetes (IU/Kg/Day), July’2020
Figure 8-36: Mixtard 30 – Recommended Minimum & Maximum Dose for Type 2 Diabetes (IU/Kg/Day), July’2020
Figure 8-37: Napa Extra – Price for 240 Tablets & Price per Unit Tablet (BDT/US$), July’2020
Figure 8-38: Napa Extra – Price for 12 Tablets & Price per Unit Tablet (BDT/US$), July’2020
Figure 8-39: Napa Extra – Minimum & Maximum Cost of Daily Treatment (BDT/US$), July’2020
Figure 8-40: Losectill – Price for 40 Capsules & Price per Unit Capsule of 10mg (BDT/US$), July’2020
Figure 8-41: Losectill – Price for 100, 120 & 500 Capsules of 20mg (BDT/US$), July’2020
Figure 8-42: Losectill – Price for 60 Capsules & Price per Unit Capsule of 40mg (BDT/US$), July’2020
Figure 8-43: Losectill – Price for 50 Sachets & Price for Single Sachet of 20mg (BDT/US$), July’2020
Figure 8-44: Losectill – Price for 30 Sachets & Price for Single Sachet of 20mg (BDT/US$), July’2020
Figure 8-45: Losectil – Recommended Minimum & Maximum Oral Dose (mg/day), July’2020
Figure 8-46: Losectil – Recommended Minimum & Maximum IV Dose (mg/day), July’2020
Figure 8-47: Napa – Price for 500 Tablet Supply & 10 Tablet Supply of 500mg (BDT/US$), July’2020
Figure 8-48: Napa – Price for 200 Tablet Supply & Price per unit Tablet of 1000mg (BDT/US$), July’2020
Figure 8-49: Napa Suspension – Price for 50ml Supply & 60ml Supply of 120mg/5ml Suspension (BDT/US$), July’2020
Figure 8-50: Napa Syrup – Price for 50ml, 60ml & 100ml Supply of 120mg/5ml Syrup (BDT/US$), July’2020
Figure 8-51: Napa Pediatric Drops – Price for 15ml Supply & Price per unit ml of 80mg/ml Drops (BDT/US$), July’2020
Figure 8-52: Napa Suppositories – Price for 20 Suppositories of various Dose Regimen (BDT/US$), July’2020
Figure 8-53: Napa IV Solution – Price for 100ml Supply & Price per unit ml of Intravenous Solution (BDT/US$), July’2020
Figure 8-54: Napa Tablet – Minimum & Maximum Recommended Adult Dose (gm/day), July’2020
Figure 8-55: Napa Tablet – Pediatric Dose by Age (mg/ 4 Times a day), July’2020
Figure 8-56: Exium – Price for 100 Capsules Supply & Price per unit Capsule of 20mg (BDT/US$), July’2020
Figure 8-57: Exium – Price for 60 Capsules Supply & Price per unit Capsule of 40mg (BDT/US$), July’2020
Figure 8-58: Exium – Price for 56 Tablets Supply & Price per unit MUPS Tablet of 20mg (BDT/US$), July’2020
Figure 8-59: Exium – Price for 28 Tablets Supply & Price per unit MUPS Tablet of 40mg (BDT/US$), July’2020
Figure 8-60: Exium – Minimum & Maximum Recommended Adult Dose (mg/day), July’2020
Figure 8-61: Exium – Minimum & Maximum Recommended Pediatric Dose (mg/day), July’2020

Figure 9-1: Bangladesh – Number of Clinical Trials by Phase, June’2020
Figure 9-2: Bangladesh – Clinical Trials by Phase (%), June’2020
Figure 9-3: Bangladesh – Number of Clinical Trials by Status, June’2020
Figure 9-4: Bangladesh – Clinical Trials by Status (%), June’2020
Figure 9-5: Bangladesh – Number of Clinical Trials by Infectious & Non Infectious Diseases (%), June’2020
Figure 9-6: Bangladesh – Number of Clinical Trials by Indications, June’2020
Figure 9-7: Bangladesh – Clinical Trials by Indication (%), June’2020

Figure 10-1: Bangladesh Pharmaceutical Market Drivers
Figure 10-2: Challenges for Bangladesh Pharmaceutical Market